Vanguard Capital Management
RCUS icon

Vanguard Capital Management’s Arcus Biosciences RCUS Stock Holding History

Vanguard Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120M Buy
3,888,346
+31,621
+0.8% +$782K ﹤0.01% 1457
2026
Q1 		$83.3M Buy
+3,856,725
New +$83.3M ﹤0.01% 1575

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's RCUS Position: Q2 2026 in Review

Vanguard Capital Management increased its Arcus Biosciences (RCUS) stake by 0.82% in Q2 2026, buying an estimated $782K and bringing the position to 3,888,346 shares worth $120M. The position accounts for ﹤0.01% of the portfolio, ranked #1457.

Vanguard Capital Management first reported a position in RCUS in Q1 2026 and has held it in 2 quarters since. 229 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Vanguard Capital Management held 3,888,346 shares of Arcus Biosciences worth $120M as of Q2 2026.
  • Vanguard Capital Management bought 31,621 Arcus Biosciences shares in Q2 2026, an estimated $782K.
  • Arcus Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1457 holding.
  • Vanguard Capital Management first reported a position in Arcus Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 229 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.